Advertisement
Advertisement
U.S. Markets open in 3 hrs 48 mins
Advertisement
Advertisement
Advertisement
Advertisement

Global Cord Blood Corporation (CO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.98760.0000 (0.00%)
At close: 02:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9876
Open2.2100
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range2.2100 - 3.3200
52 Week Range2.0300 - 5.5000
Volume7
Avg. Volume281,036
Market Cap363.146M
Beta (5Y Monthly)0.26
PE Ratio (TTM)4.92
EPS (TTM)0.6070
Earnings DateNov 22, 2022 - Nov 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 31, 2018
1y Target EstN/A
  • Business Wire

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    HONG KONG, September 26, 2022--Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant

  • Business Wire

    The Grand Court of the Cayman Islands Granted Blue Ocean’s Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    NEW YORK, September 23, 2022--Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE: CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22

  • PR Newswire

    Global Cord Blood Corporation Files Annual Report on Form 20-F

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by visiting the U.S. Securities and Exchang

Advertisement
Advertisement